-+ 0.00%
-+ 0.00%
-+ 0.00%

Gubra Kicks Off Phase 2 Trial of Obesity Drug

MT Newswires·07/16/2026 02:10:21
Listen to the news
02:10 AM EDT, 07/16/2026 (MT Newswires) -- Danish biotechnology company Gubra (GUBRA.CO) said Thursday its partner Boehringer Ingelheim began a phase 2 trial of its investigational obesity drug BI 3034701. The potential first-in-class therapy is a GLP-1/GIP/NYP2 receptor agonist designed to treat obesity through three complementary biological pathways. Gubra will receive a milestone payment of 10 million euros following the start of the study.